{"transactions":[{"id":2148738,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Scientific Officer"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-09-30T20:23:50.000Z","date":"2022-08-12","kind":"gift","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The Reporting Person has agreed to retain and not sell 478,870 RPI US LP Interests convertible into 4,788,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":478870,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-051637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122051637/doc4.xml","form_type":"4"}},{"id":2148737,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Scientific Officer"}}],"security":"Class A Ordinary Shares","published_at":"2022-09-30T20:23:50.000Z","date":"2022-09-28","kind":"sale","acquired":false,"shares":100000,"price":41.2267,"value":4122670.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $41.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":820800,"source":{"system":"sec-edgar","filing":"0001209191-22-051637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122051637/doc4.xml","form_type":"4"}},{"id":2236182,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Scientific Officer"}}],"security":"Class A Ordinary Shares","published_at":"2022-06-10T21:13:54.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":100000,"price":41.559,"value":4155900.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.37 to $41.73 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":920800,"source":{"system":"sec-edgar","filing":"0000899243-22-021954","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322021954/doc4.xml","form_type":"4"}},{"id":2251569,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Scientific Officer"}}],"security":"Class A Ordinary Shares","published_at":"2022-05-31T21:23:23.000Z","date":"2022-05-27","kind":"sale","acquired":false,"shares":75000,"price":41.0801,"value":3081007.5,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.97 to $41.16 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1020800,"source":{"system":"sec-edgar","filing":"0001209191-22-032906","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122032906/doc4.xml","form_type":"4"}},{"id":2260193,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Scientific Officer"}}],"security":"Class A Ordinary Shares","published_at":"2022-05-23T20:57:36.000Z","date":"2022-05-19","kind":"sale","acquired":false,"shares":75000,"price":40.4417,"value":3033127.5,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.35 to $40.60 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1095800,"source":{"system":"sec-edgar","filing":"0001209191-22-031366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122031366/doc4.xml","form_type":"4"}},{"id":2456255,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-12-30T23:03:24.000Z","date":"2021-09-10","kind":"gift","acquired":false,"shares":5128,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange"},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person has agreed to retain and not sell 481,270 RPI US LP Interests convertible into 4,812,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":481270,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":51280},"source":{"system":"sec-edgar","filing":"0001209191-21-071636","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919121071636/doc4.xml","form_type":"4"}},{"id":2623971,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-27T21:25:36.000Z","date":"2021-07-26","kind":"sale","acquired":false,"shares":8949,"price":39.7784,"value":355976.9016,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1170800,"source":{"system":"sec-edgar","filing":"0001209191-21-048313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919121048313/doc4.xml","form_type":"4"}},{"id":2623970,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-27T21:23:55.000Z","date":"2021-07-26","kind":"sale","acquired":false,"shares":8949,"price":39.7784,"value":355976.9016,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1170800,"source":{"system":"sec-edgar","filing":"0001209191-21-048310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919121048310/doc4.xml","form_type":"4"}},{"id":2634118,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-14T21:17:47.000Z","date":"2021-07-14","kind":"sale","acquired":false,"shares":2,"price":42,"value":84.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"balance_after":1179749,"source":{"system":"sec-edgar","filing":"0000899243-21-028334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924321028334/doc4.xml","form_type":"4"}},{"id":2634117,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-14T21:17:47.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":17832,"price":42.0077,"value":749081.3064,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.04 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1179751,"source":{"system":"sec-edgar","filing":"0000899243-21-028334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924321028334/doc4.xml","form_type":"4"}},{"id":2634116,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-14T21:17:47.000Z","date":"2021-07-12","kind":"sale","acquired":false,"shares":100,"price":42.04,"value":4204.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"balance_after":1197583,"source":{"system":"sec-edgar","filing":"0000899243-21-028334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924321028334/doc4.xml","form_type":"4"}},{"id":2638336,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-08T23:37:09.000Z","date":"2021-07-08","kind":"sale","acquired":false,"shares":40655,"price":42.046,"value":1709380.13,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1197683,"source":{"system":"sec-edgar","filing":"0000950103-21-010245","document":"dp154125_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321010245/dp154125_4-reddoch.xml","form_type":"4"}},{"id":2638335,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-08T23:37:09.000Z","date":"2021-07-07","kind":"sale","acquired":false,"shares":2192,"price":42.0104,"value":92086.7968,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1238338,"source":{"system":"sec-edgar","filing":"0000950103-21-010245","document":"dp154125_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321010245/dp154125_4-reddoch.xml","form_type":"4"}},{"id":2638334,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-07-08T23:37:09.000Z","date":"2021-07-06","kind":"sale","acquired":false,"shares":30270,"price":42.4037,"value":1283559.999,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.82 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1240530,"source":{"system":"sec-edgar","filing":"0000950103-21-010245","document":"dp154125_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321010245/dp154125_4-reddoch.xml","form_type":"4"}},{"id":2677816,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-06-09T00:12:34.000Z","date":"2021-06-08","kind":"sale","acquired":false,"shares":50000,"price":46.4308,"value":2321540.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $46.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1270800,"source":{"system":"sec-edgar","filing":"0000950103-21-008570","document":"dp152445_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008570/dp152445_4-reddoch.xml","form_type":"4"}},{"id":2677815,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-06-09T00:12:34.000Z","date":"2021-06-07","kind":"sale","acquired":false,"shares":2210,"price":47.0119,"value":103896.299,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.02 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020."}],"balance_after":1320800,"source":{"system":"sec-edgar","filing":"0000950103-21-008570","document":"dp152445_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008570/dp152445_4-reddoch.xml","form_type":"4"}},{"id":2677814,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-06-09T00:12:34.000Z","date":"2021-06-07","kind":"sale","acquired":false,"shares":47790,"price":46.5688,"value":2225522.952,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.99 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020."}],"balance_after":1323010,"source":{"system":"sec-edgar","filing":"0000950103-21-008570","document":"dp152445_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008570/dp152445_4-reddoch.xml","form_type":"4"}},{"id":2677813,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-06-09T00:12:34.000Z","date":"2021-06-04","kind":"sale","acquired":false,"shares":100000,"price":44.5973,"value":4459730.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.14 to $45.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1370800,"source":{"system":"sec-edgar","filing":"0000950103-21-008570","document":"dp152445_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008570/dp152445_4-reddoch.xml","form_type":"4"}},{"id":2681109,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-06-04T22:50:20.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":50000,"price":42.1312,"value":2106560.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1470800,"source":{"system":"sec-edgar","filing":"0000950103-21-008457","document":"dp152318_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008457/dp152318_4-reddoch.xml","form_type":"4"}},{"id":2718832,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-05-12T01:06:39.000Z","date":"2021-05-07","kind":"exercise","acquired":false,"shares":132080,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person has agreed to retain and not sell 485,118 RPI US LP Interests convertible into 4,851,180 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":486398,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1320800},"source":{"system":"sec-edgar","filing":"0000950103-21-007078","document":"dp150859_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007078/dp150859_4-reddoch.xml","form_type":"4"}},{"id":2718831,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-05-12T01:06:39.000Z","date":"2021-05-07","kind":"exercise","acquired":true,"shares":1320800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":1520800,"source":{"system":"sec-edgar","filing":"0000950103-21-007078","document":"dp150859_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007078/dp150859_4-reddoch.xml","form_type":"4"}},{"id":2747199,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-04-16T21:56:26.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":55714,"price":42.1006,"value":2345592.8284,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.45 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0000950103-21-005663","document":"dp149488_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321005663/dp149488_4-reddoch.xml","form_type":"4"}},{"id":2749639,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-04-14T11:51:30.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":359,"price":42.32,"value":15192.88,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"balance_after":255714,"source":{"system":"sec-edgar","filing":"0000950103-21-005529","document":"dp149383_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321005529/dp149383_4-reddoch.xml","form_type":"4"}},{"id":2773270,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-24T21:25:18.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":43927,"price":46.3159,"value":2034518.5393,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $47.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":256073,"source":{"system":"sec-edgar","filing":"0000950103-21-004522","document":"dp148366_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321004522/dp148366_4-reddoch.xml","form_type":"4"}},{"id":2809138,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-05T00:02:13.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":3510,"price":47.842,"value":167925.42,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.54 to $48.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0000950103-21-003569","document":"dp147386_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003569/dp147386_4-reddoch.xml","form_type":"4"}},{"id":2809137,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-03-05T00:02:13.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":96490,"price":46.8881,"value":4524232.769,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.45 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":303510,"source":{"system":"sec-edgar","filing":"0000950103-21-003569","document":"dp147386_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321003569/dp147386_4-reddoch.xml","form_type":"4"}},{"id":2921265,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-01-06T02:45:10.000Z","date":"2020-12-31","kind":"exercise","acquired":false,"shares":12990,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes RPI US LP Interests convertible into 4,851,184 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances."}],"balance_after":618478,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":129900},"source":{"system":"sec-edgar","filing":"0000950103-21-000105","document":"dp143911_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000105/dp143911_4-reddoch.xml","form_type":"4"}},{"id":2921264,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-01-06T02:45:10.000Z","date":"2020-12-31","kind":"exercise","acquired":false,"shares":27010,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes RPI US LP Interests convertible into 21,070 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":2107,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":270100},"source":{"system":"sec-edgar","filing":"0000950103-21-000105","document":"dp143911_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000105/dp143911_4-reddoch.xml","form_type":"4"}},{"id":2921263,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-01-06T02:45:10.000Z","date":"2020-12-31","kind":"exercise","acquired":true,"shares":129900,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0000950103-21-000105","document":"dp143911_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000105/dp143911_4-reddoch.xml","form_type":"4"}},{"id":2921262,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2021-01-06T02:45:10.000Z","date":"2020-12-31","kind":"exercise","acquired":true,"shares":270100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":270100,"source":{"system":"sec-edgar","filing":"0000950103-21-000105","document":"dp143911_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321000105/dp143911_4-reddoch.xml","form_type":"4"}},{"id":3103269,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-23T01:56:05.000Z","date":"2020-06-18","kind":"exercise","acquired":false,"shares":2503,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes RPI Intl. LP Interests convertible into 1,950 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":195,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":25030},"source":{"system":"sec-edgar","filing":"0000950103-20-012151","document":"dp130797_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012151/dp130797_4-reddoch.xml","form_type":"4"}},{"id":3103268,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"ICAI Interests","published_at":"2020-06-23T01:56:05.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These ICAI Interests represent a grant of up to 200,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"These ICAI Interests represent a grant of up to 200,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":200000,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950103-20-012151","document":"dp130797_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012151/dp130797_4-reddoch.xml","form_type":"4"}},{"id":3103267,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-23T01:56:05.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":2698,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes RPI Intl. LP Interests convertible into 1,950 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":2698,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":26980},"source":{"system":"sec-edgar","filing":"0000950103-20-012151","document":"dp130797_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012151/dp130797_4-reddoch.xml","form_type":"4"}},{"id":3103266,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-23T01:56:05.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":631468,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes RPI US LP Interests convertible into 4,851,184 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances."}],"balance_after":631468,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":6314680},"source":{"system":"sec-edgar","filing":"0000950103-20-012151","document":"dp130797_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012151/dp130797_4-reddoch.xml","form_type":"4"}},{"id":3103265,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-23T01:56:05.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":29117,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reddoch RPI LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes RPI US LP Interests convertible into 21,070 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":29117,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":291170},"source":{"system":"sec-edgar","filing":"0000950103-20-012151","document":"dp130797_4-reddoch.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012151/dp130797_4-reddoch.xml","form_type":"4"}},{"id":3103264,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":123444,"kind":"person","name":"Reddoch James F.","position":1,"cik":"0001814872","reported_name":"Reddoch James F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-23T01:56:05.000Z","date":"2020-06-18","kind":"exercise","acquired":true,"shares":25030,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":25030,"source":{"system":"sec-edgar","filing":"0000950103-20-012151","document":"dp130797_4-reddoch.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012151/dp130797_4-reddoch.xml","form_type":"4"}}]}